Vertex Pharmaceuticals Incorporated (VRTX) – CF drugs providing success to the company

in , , on September 15, 2022

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

Vertex Pharmaceuticals Incorporated (VRTX)

VRTX is a leading company in biomedical and genetics industry. It holds a monopoly in Cystic fibrosis market. The companies in the sector try to remain ahead through new product developments. This is important for their long term success.



– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance


Stock Price Performance

Crispidea Coverage

No of Pages : 33

Release Information

  • Price


  • Released

    September 15, 2022

  • Last Updated

    September 20, 2022